Logo yposkesi
waves image

About us

Team Yposkesi CDMO

Best-in-Class CDMO

Yposkesi, an SK pharmteco company, is one of Europe’s largest Contract Development and Manufacturing Organizations (CDMO) for gene therapy viral vector manufacturing. A one-stop shop for biotechs and pharma seeking to advance clinical trials and commercialize new Advanced Therapy Medicinal Products (ATMPs), Yposkesi offers a full range of services in lentiviral vectors & AAV (Adeno-Associated Virus) cGMP manufacturing.

pharma gene therapy factory

The experts behind the expertise: our story

The Yposkesi story begins with the AFM-Telethon, the French Muscular Dystrophy Association, and a mission to make innovative therapies accessible to patients with genetic disorders and other disabilities. AFM-Telethon had originally created Genethon and CECS/I-Stem, two-world-class R&D centers developing respectively gene- and cell-therapies for orphan genetic diseases from research to clinical validation, with an early focus on biomanufacturing since 2006. Leveraging on this unique expertise and knowledge, Yposkesi was launched in November 2016. Since March 2021, Yposkesi welcomed SK Inc., as its main shareholder.

Yposkesi building

Driving innovation in high quality viral vector manufacturing for gene therapy developers

Located in the Genepole Innovation campus in Corbeil-Essonnes (South of Paris) in France, Yposkesi’s current 50,000 ft2 (approx. 5,000m2) facility operates multiple manufacturing suites for bulk drug substance (up to 1,000L) and Fill & Finish to support the growing demand for late-phase projects.
In 2023, Yposkesi will bring online additional capacity by increasing its global footprint to 100,000 ft2 (approx. 10,000m2) with a second large-scale facility designed for EMA and FDA compliance.

Viral vector manufacturing

Viral vector manufacturing in one of Europe’s largest facilities

Being a pioneer in his field, Yposkesi is one of the largest AAV and lentiviral vectors production facility in Europe. With our facilities expending by 2023, this will further strengthening Yposkesi’s lead.
We know that time is of essence in clinical development of new therapies, and manufacturing is often a bottleneck for gene therapy manufacturers. The sheer size of our cGMP facility, dedicated technical team and expertise enable us to readily accommodate new projects and meet the on-time demands of our clients breaking ground in therapeutic treatments.

Our services